A protein known for controlling inflammation could eventually guide scientists to fresh approaches for easing frailty and bone weakening tied to getting older, although current data come only from mouse experiments. Researchers at the University at Buffalo identified tristetraprolin, or TTP, as a possible focus for limiting certain negative impacts of aging. Raising levels of this protein in older mice led to improved grip strength, walking ability, stamina, and general physical function, according to biologist Keith Kirkwood. The results do not represent a therapy and remain distant from human testing. They nevertheless contribute to evidence linking ongoing inflammation to bodily decline over time. The authors state that these outcomes make TTP a promising focus for tackling frailty and inflammation linked to aging and open doors to wider treatment research. Nearly one quarter of Americans are projected to reach age 65 or above by 2050, marking more than a 40 percent rise from 58 million in 2022 to 82 million. Many individuals are anticipated to reach their nineties or beyond. Declining birth rates, medical progress, and extended lifespans drive rising average ages both nationally and worldwide. While longer life may seem desirable, questions remain about whether healthcare systems can support aging groups while maintaining strength, movement, and self-reliance. A key issue involves inflammaging, the persistent low-level inflammation that often grows with age. Such immune shifts, termed immunosenescence, reduce resilience and raise vulnerability to chronic inflammatory conditions common in later years, Kirkwood notes. In mouse models, the team observed that TTP supports several protective roles, such as limiting various cytokines. These signaling proteins guide immune activity, yet prolonged overactivity can fuel lasting inflammation. TTP appears in multiple tissues including skin, muscle, nerve cells, and connective structures. Earlier studies indicate its levels drop with age, particularly within the immune system. To examine effects of keeping TTP steadier during aging, scientists used genetically modified mice with stabilized and elevated TTP expression. Enhancing this protein in 22-month-old mice of both sexes reduced frailty and boosted functional health measures. The modified mice showed stronger physical performance in grip, walking speed, treadmill endurance, and daily activity. Gains appeared more clearly in males, with some results matching those of younger six-month-old animals. They also displayed higher bone density and thickness, reflecting improved skeletal structure. Kirkwood reports they showed a younger immune profile. Certain fitness and bone gains occurred mainly in males, possibly linked to falling estrogen in females that normally shields tissues and affects cytokine signals. Human trials remain distant, and efforts to screen drugs for raising TTP have not succeeded yet. Next steps include examining TTP effects on brain inflammation tied to conditions like Alzheimer’s. The mouse stabilization method cannot transfer directly to people, yet researchers suggest small-molecule inducers or phosphorylation modifiers might achieve comparable results. Kirkwood expresses optimism about future directions. The work adds an interesting element to ongoing anti-aging research. Advanced age brings higher inflammation and weaker immunity, making new treatments important for chronic issues such as arthritis.
